
Company Updates ·
Scienture expects preliminary third-quarter revenue of about $1.22 million
Preliminary revenue rose 256% from the second quarter after the REZENOPY launch and higher Arbli wholesale unit sales. The figures are unaudited.
SCNX Scienture Holdings, Inc.

Company Updates ·
Preliminary revenue rose 256% from the second quarter after the REZENOPY launch and higher Arbli wholesale unit sales. The figures are unaudited.
Revenue rose from $56,325 in the first quarter, gross margin was approximately 97.7% and the net loss narrowed to about $2.8 million. The company began commercial launch of REZENOPY during the quarter.
Eric Sherb resigned as chief financial officer on May 26, 2026. Dr. Narasimhan Mani, already a director and Co-Chief Executive Officer, took the interim role the same day.
Revenue rose 449% from a year earlier on more Arbli orders. The company also reported $11.0 million of non-dilutive debt financing.
The April 27, 2026 agreement issued an A-1 note and a B note to Streeterville Capital, LLC. Maxim Group LLC served as placement agent.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $2.0 million | $2.2 million |
| Net income (loss) | -$41.5 million | $9.1 million |
| Cash from operations | -$13.4 million | -$14.3 million |
| Cash and equivalents | $6.7 million | $308,096 |
Scienture Holdings, Inc. trades under the ticker SCNX on NASDAQ.
Scienture Holdings, Inc. is listed on NASDAQ.
Our directory records Scienture Holdings, Inc. under United States.
aibio.space lists Scienture Holdings, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Scienture Holdings, Inc. reported a net loss of $41.5 million for the fiscal year ended Dec 31, 2025, and used $13.4 million of cash in operations, per its annual report to the SEC.
$2.0 million in the fiscal year ended Dec 31, 2025, per its annual report.
$8.2 million in cash at Jun 30, 2026, per its 10-Q.
Our latest story on Scienture Holdings, dated Oct 13, 2026: "Scienture expects preliminary third-quarter revenue of about $1.22 million". Preliminary revenue rose 256% from the second quarter after the REZENOPY launch and higher Arbli wholesale unit sales. The figures are unaudited. Source.
Our latest debt story, dated Apr 27, 2026: "Scienture closes $8 million note purchase with Streeterville Capital". The April 27, 2026 agreement issued an A-1 note and a B note to Streeterville Capital, LLC. Maxim Group LLC served as placement agent. Source.
Press Follow on this page to add Scienture Holdings to your Following list, or subscribe to the aibio.space newsletter. We have published 5 stories naming Scienture Holdings so far, in Company Updates, Debt Financing.
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction